Devonian Health Group Inc.

GSD

CA2518341078

Pharmaceuticals

Delayed Toronto S.E. Other stock markets 15:57:28 2024-05-21 EDT			5-day change	1st Jan Change
0.195 ^CAD	-2.50%		-2.50%	+34.48%

03-28	Devonian Health Group Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	CI
03-14	Devonian Health Group Closes Non-Brokered Private Placement; Down Nearly 7%	MT

Devonian Health Group Inc. Appoints Borys Chabursky, Sybil Dahan and Terry L. Fretz as Directors

January 12, 2018 at 10:21 am

Devonian Health Group Inc. announced at the annual general and special meeting held on January 11, 2018, the shareholders appointed Borys Chabursky, Sybil Dahan and Terry L. Fretz as directors.

Latest news about Devonian Health Group Inc.

Devonian Health Group Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	03-28	CI
Devonian Health Group Closes Non-Brokered Private Placement; Down Nearly 7%	03-14	MT
Devonian Health Group Inc. announced that it has received CAD 0.2238 million in funding	03-12	CI
Devonian Health Group Inc. Appoints Kathryn J. Gregory to the Board	02-29	CI
Devonian Announces $2.16 Million Secured Term Loan Following Repayment of $3.5 Million Long Term Loan	02-26	CI
Devonian Health Group Inc. Reports Earnings Results for the First Quarter Ended October 31, 2023	12-22	CI
Devonian Health Group Inc. Announces CEO Changes	12-04	CI
Devonian Health Group Inc. Announces Changes to its Board	12-04	CI
Devonian Health Group Inc. Reports Earnings Results for the Full Year Ended July 31, 2023	11-28	CI
Devonian Health Group Inc. Files Patent Cooperation Treaty Application for Thykamine?? in Wound Healing	11-08	CI
Devonian Health Group Inc. announced that it has received CAD 0.5 million in funding	23-08-31	CI
Devonian Health Group Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023	23-06-28	CI
Devonian Health Group Inc. announced that it has received CAD 1.199665 million in funding	23-06-05	CI
Devonian Health Group Plans to Raise Up To $5 Million via Private Placement	23-05-19	MT
Devonian Health Group Inc. announced that it expects to receive CAD 5 million in funding	23-05-18	CI
Devonian Health Group Announces Presentation of ThykamineTM Efficacy Results in Atopic Dermatitis at the World Congress of Dermatology and Provides ThykamineTM Clinical Development Program Update	23-05-16	CI
Devonian Health Group Announces the Appointment of New Board Members	23-05-12	CI
Devonian Health Group Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023	23-03-24	CI
Devonian Health Group Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023	23-03-24	CI
Devonian Health Group Inc. Announces Executive Appointments	23-03-24	CI
Devonian Health Group Inc. Announces Executive Changes	23-01-06	CI
Devonian Health Group Inc. Reports Earnings Results for the First Quarter Ended October 31, 2022	22-12-22	CI
Devonian Health Group Inc. Reports Earnings Results for the Full Year Ended July 31, 2022	22-11-28	CI
Devonian Health Group Inc. Auditor Raises 'Going Concern' Doubt	22-11-27	CI
Devonian Health Group Inc. to Present ThykamineTM Phase 2 Clinical Results at the 6th Dermatology Drug Development Summit for Inflammatory Skin Diseases	22-10-12	CI

Chart Devonian Health Group Inc.

Duration

Period

More charts

Devonian Health Group Inc. is a Canada-based late-stage botanical pharmaceutical company. The Company's main activity is the development of botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases, including ulcerative colitis and atopic dermatitis. It is also involved in the development of value-added products for dermo-cosmetics and the distribution of pharmaceutical products through its subsidiary. The Companyâs flagship product, Thykamine, the pharmaceutical product issued from its SUPREX platform, is a product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The Companyâs flagship product, Thykamine, the pharmaceutical product issued from its SUPREX platform, is a product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The Company's cosmeceutical products include R-Spinasome and Purgenesis.

Sector

Pharmaceuticals

Calendar

2024-06-25 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
DEVONIAN HEALTH GROUP INC.	+34.48%	21.14M
ELI LILLY AND COMPANY	+40.03%	723B
NOVO NORDISK A/S	+34.28%	595B
JOHNSON & JOHNSON	-3.75%	369B
MERCK & CO., INC.	+20.43%	332B
ABBVIE INC.	+3.09%	282B
ASTRAZENECA PLC	+17.02%	244B
NOVARTIS AG	+9.31%	208B
ROCHE HOLDING AG	-5.07%	205B
PFIZER, INC.	+0.36%	168B